| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 156, Issue 6 2294-2299, Copyright © 1996 by American Association of Immunologists
ARTICLES |
TA Judge, A Tang, LM Spain, J Deans-Gratiot, MH Sayegh and LA Turka
Department of Medicine, University of Pennsylvania, Philadelphia 19104, USA.
A single dose of CTLA4Ig, an inhibitor of CD28-mediated T cell costimulation, given 2 days after transplantation induces specific unresponsiveness to alloantigens in vivo. However, the mechanisms responsible are unknown. Using pigeon cytochrome c as a model Ag, we monitored the effect of CTLA4Ig on the fate of Ag-reactive T cells in normal mice and on pigeon cytochrome c-specific TCR transgenic cells adoptively transferred into congenic mice. CTLA4Ig significantly inhibits immunization with pigeon cytochrome c. In particular, ELISA and ELISPOT assays indicate an 80 to 90% reduction in Th1 (i.e, IL-2 and IFN-gamma) cytokine production and in the numbers of cytokine- producing cells. Interestingly, despite this profound reduction in cytokine-producing cells, Ag-reactive T cells expand in CTLA4Ig-treated animals, although the degree of expansion is reduced by 50% compared with that in control Ig-treated animals. Thus, loss of Th1 cytokine production in CTLA4Ig-treated animals is not fully explained by the decreased expansion of Ag-specific T cells. These results suggest two mechanisms of action for CTLA4Ig in vivo: inhibition of expansion of Ag- reactive cells and induction of anergy in the residual population.
This article has been cited by other articles:
|
|
 |
|
  R. SCRIVO, M. DI FRANCO, A. SPADARO, and G. VALESINI The Immunology of Rheumatoid Arthritis Ann. N.Y. Acad. Sci., June 1, 2007; 1108(1): 312 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. V. Sweet Abatacept. Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2065 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Davidson, B Diamond, D Wofsy, and D Daikh Block and tackle: CTLA4Ig takes on lupus Lupus, March 1, 2005; 14(3): 197 - 203. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Machen, J. Harnaha, R. Lakomy, A. Styche, M. Trucco, and N. Giannoukakis Antisense Oligonucleotides Down-Regulating Costimulation Confer Diabetes-Preventive Properties to Nonobese Diabetic Mouse Dendritic Cells J. Immunol., October 1, 2004; 173(7): 4331 - 4341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Elhalel, J.-H. Huang, W. Schmidt, J. Rachmilewitz, and M. L. Tykocinski CTLA-4 {middle dot} FasL Induces Alloantigen-Specific Hyporesponsiveness J. Immunol., June 15, 2003; 170(12): 5842 - 5850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Lee, J. R. Rusche, M. E. Maloney, D. H. Sachs, M. H. Sayegh, and J. C. Madsen CTLA4Ig-Induced Linked Regulation of Allogeneic T Cell Responses J. Immunol., February 1, 2001; 166(3): 1572 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Guillot, P. Mathieu, H. Coathalem, B. Le Mauff, M. G. Castro, L. Tesson, C. Usal, T. Laumonier, S. Brouard, J.-P. Soulillou, et al. Tolerance to Cardiac Allografts Via Local and Systemic Mechanisms After Adenovirus-Mediated CTLA4Ig Expression J. Immunol., May 15, 2000; 164(10): 5258 - 5268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. GUDMUNDSDOTTIR and L. A. TURKA T Cell Costimulatory Blockade: New Therapies for TransplantRejection J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1356 - 1365. [Abstract] [Full Text]
|
|
|
|
|
|
H. Gudmundsdottir, A. D. Wells, and L. A. Turka Dynamics and Requirements of T Cell Clonal Expansion In Vivo at the Single-Cell Level: Effector Function Is Linked to Proliferative Capacity J. Immunol., May 1, 1999; 162(9): 5212 - 5223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Judge, Z. Wu, X.-G. Zheng, A. H. Sharpe, M. H. Sayegh, and L. A. Turka The Role of CD80, CD86, and CTLA4 in Alloimmune Responses and the Induction of Long-Term Allograft Survival J. Immunol., February 15, 1999; 162(4): 1947 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Maxwell, J. D. Campbell, C. H. Kim, and A. T. Vella CD40 Activation Boosts T Cell Immunity In Vivo by Enhancing T Cell Clonal Expansion and Delaying Peripheral T Cell Deletion J. Immunol., February 15, 1999; 162(4): 2024 - 2034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Schweitzer and A. H. Sharpe Studies Using Antigen-Presenting Cells Lacking Expression of Both B7-1 (CD80) and B7-2 (CD86) Show Distinct Requirements for B7 Molecules During Priming Versus Restimulation of Th2 But Not Th1 Cytokine Production J. Immunol., September 15, 1998; 161(6): 2762 - 2771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. de Leval, S. Colombi, S. Debrus, M.-A. Demoitie, R. Greimers, P. Linsley, M. Moutschen, and J. Boniver CD28-B7 Costimulatory Blockade by CTLA4Ig Delays the Development of Retrovirus-Induced Murine AIDS J. Virol., June 1, 1998; 72(6): 5285 - 5290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Konieczny, Z. Dai, E. T. Elwood, S. Saleem, P. S. Linsley, F. K. Baddoura, C. P. Larsen, T. C. Pearson, and F. G. Lakkis IFN-{gamma} Is Critical for Long-Term Allograft Survival Induced by Blocking the CD28 and CD40 Ligand T Cell Costimulation Pathways J. Immunol., March 1, 1998; 160(5): 2059 - 2064. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
